NRX Pharmaceuticals, Inc. — Investor Relations & Filings
NRx Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company developing therapeutics for central nervous system (CNS) disorders. The company focuses on addressing high unmet medical needs for patients with life-threatening conditions, particularly suicidal depression, suicidal bipolar depression, and post-traumatic stress disorder (PTSD). Its development pipeline is based on its N-methyl-D-aspartate (NMDA) receptor platform. The lead candidate, NRX-101, is an investigational oral medication for suicidal bipolar depression that has received Breakthrough Therapy and Fast Track designations from the U.S. Food and Drug Administration (FDA). Other key programs include NRX-100 for suicidal ideation and KETAFREE™, a preservative-free ketamine product.
Recent filings
| Filing | Released | Lang | Actions |
|---|---|---|---|
| FORM 10-Q | 2026-05-15 | English | |
| 10-K - NRX Pharmaceuticals, Inc. (0001719406) (Filer) | 2026-03-23 | English | |
| NRx Builds Momentum From FDA Progress To Strategic Expansion | 2026-02-27 | English | |
| ARS - NRX PHARMACEUTICALS, INC. (0001719406) (Filer) | 2026-02-23 | English | |
| DEF 14A - NRX PHARMACEUTICALS, INC. (0001719406) (Filer) | 2026-02-23 | English | |
| 3 Filing | 2026-02-17 | English |
Browse filings by year
10 years| ID | Filing | Released | Lang | Actions | |
|---|---|---|---|---|---|
|
2026
12 filings
| |||||
| 46362258 | FORM 10-Q | 2026-05-15 | English | ||
| 33016320 | 10-K - NRX Pharmaceuticals, Inc. (0001719406) (Filer) | 2026-03-23 | English | ||
| 32842675 | NRx Builds Momentum From FDA Progress To Strategic Expansion | 2026-02-27 | English | ||
| 32897212 | ARS - NRX PHARMACEUTICALS, INC. (0001719406) (Filer) | 2026-02-23 | English | ||
| 32897213 | DEF 14A - NRX PHARMACEUTICALS, INC. (0001719406) (Filer) | 2026-02-23 | English | ||
| 31455206 | 3 Filing | 2026-02-17 | English | ||
| 31455134 | 8-K Filing | 2026-02-17 | English | ||
| 31455132 | 4 Filing | 2026-02-17 | English | ||
| 31455059 | 8-K Filing | 2026-02-17 | English | ||
| 31455038 | 424B5 Filing | 2026-02-17 | English | ||
| 31455029 | 8-K Filing | 2026-02-02 | English | ||
| 13065785 | FORM 8-K | 2026-01-16 | English | ||
|
2025
3 filings
| |||||
| 13065786 | FORM 8-K | 2025-12-29 | English | ||
| 13065787 | Regulatory Filings 2025 | 2025-12-23 | English | ||
| 13065788 | FORM 424B3 | 2025-12-22 | English | ||
Market data
Market data not available
Price history
Peer group · Manufacture of pharmaceuticals, medicinal chemical and botanical products
| Company | Ticker | Country | Sector |
|---|---|---|---|
|
AC Immune SA
Biopharmaceutical firm developing precision medicine for ne…
|
ACIU | CH | Manufacturing |
|
Aclaris Therapeutics, Inc.
Clinical-stage biopharmaceutical company developing drugs f…
|
ACRS | US | Manufacturing |
|
Acrivon Therapeutics, Inc.
Clinical-stage biopharma using proteomics to develop precis…
|
ACRV | US | Manufacturing |
|
ACRUX LIMITED
Develops and commercializes topical and transdermal drug de…
|
ACR | AU | Manufacturing |
|
Acticor Biotech
Develops treatments for thrombotic diseases, focusing on ac…
|
ALACT | FR | Manufacturing |
|
Actinium Pharmaceuticals, Inc.
Clinical-stage company developing targeted radiotherapies f…
|
ATNM | US | Manufacturing |
|
ACTUATE THERAPEUTICS, INC.
Clinical-stage biopharma developing therapies for cancers w…
|
ACTU | US | Manufacturing |
|
AcuCort AB
Develops user-friendly drug formulations for severe and acu…
|
ACUC | SE | Manufacturing |
|
Acumen Pharmaceuticals, Inc.
Clinical-stage biopharma developing targeted therapies for …
|
ABOS | US | Manufacturing |
|
Acurx Pharmaceuticals, Inc.
Clinical-stage biopharma developing a new class of antibiot…
|
ACXP | US | Manufacturing |
NRX Pharmaceuticals, Inc. via the API
Pull this company's filings, identifiers, and metadata as JSON or Markdown. Authenticate with your API key, then query by company ID, ISIN, or LEI. Full schema documented in the OpenAPI spec.
Endpoints
| GET | /api/companies/34346/ | Company identity, sector, listing, identifiers |
| GET | /api/filings/?company=34346 | Paginated list of all filings (filterable by type, date, language) |
| GET | /api/filings/{id}/ | Single filing — metadata, document URL, processing status |
| GET | /api/filings/{id}/markdown/ | Filing content as Markdown (PDF → text/tables/figures) |
| GET | /api/isins/?company=34346 | All ISINs registered to this company |
| GET | /api/filing-types/ | Reference: every filing-type code + category |
cURL
$ curl https://api.financialreports.eu/api/filings/?company=34346 \ -H "x-api-key: $FR_API_KEY" \ -H "Accept: application/json"
Python
import requests r = requests.get( "https://api.financialreports.eu/api/filings/", params={"company": 34346}, headers={"x-api-key": API_KEY}, ) filings = r.json()["results"]
MCP server
// MCP server URL https://mcp.financialfilings.com/mcp // Once connected, the LLM can query this company directly: "Pull the latest 5 filings for NRX Pharmaceuticals, Inc. (id: 34346)"
Report missing filing
Can't find a specific document? Let us know and we'll add it within 24 hours.